Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bolt Biotherapeutics, Inc. (BOLT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0200-0.1300 (-6.05%)
At close: 04:00PM EDT
2.0600 +0.04 (+1.98%)
After hours: 06:15PM EDT
Advertisement

Bolt Biotherapeutics, Inc.

900 Chesapeake Drive
Redwood City, CA 94063
United States
650 665 9295
https://www.boltbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees91

Key Executives

NameTitlePayExercisedYear Born
Dr. Randall C. Schatzman Ph.D.CEO & Director830.67kN/A1955
Dr. Edgar G. Engleman M.D.Founder & Independent Director31.58kN/A1946
Mr. William P. QuinnCFO & Sec.563.68kN/A1971
Mr. Grant Yonehiro C.F.A., M.B.A.Chief Bus. Officer519.98kN/A1964
Dr. Edith A. Perez M.D.Chief Medical Officer627.32kN/A1957
Dr. David Dornan Ph.D.Advisor580.08kN/A1978
Ms. Karen L. BergmanVP of Communications & Investor RelationsN/AN/AN/A
Mr. Wesley BurwellVP & Head of HRN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Corporate Governance

Bolt Biotherapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement